Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors

نویسندگان

چکیده

Background: The presented phase I, first-in-human study evaluated the tolerance, pharmacokinetics, and preliminary efficacy of larotinib mesylate in patients with advanced solid tumors. Methods: Cancer were assigned to receive at 50–400 mg dose levels until disease progression or intolerance. Dose-limiting toxicities assessed during Cycles 0 1. Pharmacokinetic evaluations performed after first steady-state. Results: Twenty-five tumors enrolled dose-escalation study. No DLTs observed. Acne-like rash (68.0%), diarrhea (48.0%), paronychia anemia (48.0%) most reported treatment-related adverse events. clear linear pharmacokinetic characteristic could be drawn, obvious accumulation was Two non-small cell lung cancer experienced a partial response, 15 had stable treatment. Conclusion: Continuous oral administration daily demonstrated favorable safety profile, anti-tumor activity observed

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors.

PURPOSE BIBF 1120 is an oral, potent angiokinase inhibitor targeting receptors of the vascular endothelial growth factors, platelet-derived growth factors, and fibroblast growth factors. This phase I, accelerated titration study assessed the maximum tolerated dose, safety, pharmacokinetics, and pharmacodynamic effects of BIBF 1120. PATIENTS AND METHODS Sixty-one patients with advanced cancers...

متن کامل

Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.

PURPOSE Bortezomib (PS-341), a first-in-class proteasome inhibitor, is metabolized by deboronation involving cytochrome P4503A (CYP3A), which also metabolizes docetaxel. Preclinical studies have shown synergy between bortezomib and taxanes. We conducted a phase I study combining bortezomib and docetaxel in refractory solid tumor patients. EXPERIMENTAL DESIGN Patients received escalating doses...

متن کامل

Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors.

PURPOSE Sorafenib and erlotinib are potent, orally administered receptor tyrosine kinase inhibitors with antiproliferative and antiangiogenic activities. Given their inhibitory target profile and efficacy as single agents, the combination of these drugs is of considerable interest in solid malignancies. This study aimed to determine the recommended phase II dose of this targeted combination, th...

متن کامل

Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors.

PURPOSE To assess the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacodynamics, and antitumor activity of continuous weekly-administered paclitaxel and BMS-214662, a novel farnesyl transferase inhibitor. EXPERIMENTAL DESIGN Patients were treated every week as tolerated with i.v. paclitaxel (fixed dose, 80 mg/m(2)/wk) administered over 1 h followed by i.v. BMS-214662 (escal...

متن کامل

Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors

PURPOSE OPB-31121 is an oral STAT3 inhibitor with a good preclinical antitumor activity. This phase I dose-escalation study of OPB-31121 was conducted to determine maximum-tolerated dose (MTD), safety, pharmacokinetics, and preliminary antitumor efficacy in patients with advanced solid tumors. MATERIALS AND METHODS Patients received OPB-31121 once daily for 28 days of each cycle followed by 2...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Frontiers in Pharmacology

سال: 2021

ISSN: ['1663-9812']

DOI: https://doi.org/10.3389/fphar.2021.636324